Astria Therapeutics' (ATXS) shares were up nearly 3% in recent Friday trading after JMP Securities initiated the company's stock at outperform.
This comes days after the company started its phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis. Early proof-of-concept results are expected in Q3.
Trading volume stood at over 162,000 shares against a daily average of about 323,000 shares.
Price: 7.70, Change: +0.21, Percent Change: +2.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.